Riding On Exosome Potential, Evox Eyes Unicorn Status
UK Firm Completes £69.2m Series C Financing
Executive Summary
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.
You may also be interested in...
Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
BioInvent Banks $116m As NHL Drug Nears Phase III
Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.
Need a specific report? 1000+ reports available
Buy Reports